Brokerages Expect Alpine Immune Sciences Inc (ALPN) Will Post Earnings of -$0.60 Per Share

Share on StockTwits

Wall Street brokerages predict that Alpine Immune Sciences Inc (NASDAQ:ALPN) will post earnings of ($0.60) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Alpine Immune Sciences’ earnings, with estimates ranging from ($0.72) to ($0.51). Alpine Immune Sciences reported earnings of ($0.33) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 81.8%. The firm is expected to issue its next earnings results on Wednesday, March 27th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full year earnings of ($2.12) per share for the current fiscal year, with EPS estimates ranging from ($2.32) to ($1.98). For the next fiscal year, analysts expect that the firm will post earnings of ($2.46) per share, with EPS estimates ranging from ($2.85) to ($1.94). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.31). Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 26.00%.

ALPN has been the topic of several recent analyst reports. ValuEngine downgraded shares of Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Thursday, November 1st. Raymond James initiated coverage on shares of Alpine Immune Sciences in a report on Monday, August 13th. They set a “buy” rating and a $13.00 price objective on the stock. Zacks Investment Research downgraded shares of Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, October 16th. Finally, Piper Jaffray Companies initiated coverage on shares of Alpine Immune Sciences in a report on Thursday, September 27th. They set an “overweight” rating and a $12.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $12.67.

Large investors have recently modified their holdings of the stock. DRW Securities LLC raised its holdings in shares of Alpine Immune Sciences by 138.7% during the 2nd quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 14,143 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Alpine Immune Sciences by 20.9% during the 2nd quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after acquiring an additional 21,124 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Alpine Immune Sciences by 122.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 18,052 shares during the period. Institutional investors own 56.87% of the company’s stock.

Shares of ALPN traded down $0.01 during mid-day trading on Monday, hitting $4.80. 9,821 shares of the company traded hands, compared to its average volume of 15,467. Alpine Immune Sciences has a 1-year low of $4.61 and a 1-year high of $11.75. The company has a quick ratio of 20.99, a current ratio of 20.99 and a debt-to-equity ratio of 0.05. The company has a market cap of $66.77 million, a P/E ratio of -4.00 and a beta of 0.94.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Featured Article: Short Selling

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.